UNCY · Unicycive Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.61M | - | $2.96M | $1.75M | $2.17M | - | $3.04M | $4.87M | $6.81M | - |
| SG&A | $6.83M | - | $4.38M | $5.21M | $5.82M | - | $3.21M | $2.53M | $2.39M | - |
| Total Operating Expenses | $8.44M | - | $7.34M | $6.96M | $7.99M | - | $6.25M | $7.40M | $9.20M | - |
| D&A | $8.0K | - | - | - | $8.0K | - | - | - | $9.0K | - |
| Operating Income | ($8.44M) | - | ($7.34M) | ($6.96M) | ($7.99M) | - | ($6.25M) | ($7.40M) | ($9.20M) | - |
| Interest Expense | - | - | $15.0K | $13.0K | $20.0K | - | $15.0K | $16.0K | $20.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($12.82M) | - | ($6.01M) | ($6.45M) | $570.0K | - | ($4.10M) | $9.86M | ($20.96M) | - |
| EPS - Basic | ($0.54) | - | ($0.33) | ($0.52) | - | - | ($0.50) | $0.80 | ($6.10) | - |
| EPS - Diluted | ($0.54) | - | ($0.33) | ($0.52) | ($0.50) | - | ($0.50) | ($1.50) | ($6.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.37M | $29.20M | $42.70M | $22.33M | $26.14M | $26.14M | $32.35M | $41.78M | $48.93M | $9.70M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.14M | $383.0K | $957.0K | $775.0K | $1.40M | $1.06M | $548.0K | $1.47M | $1.24M | $839.0K |
| Current Assets | $63.55M | $48.96M | $50.29M | $29.53M | $27.35M | $30.95M | $37.74M | $44.05M | $51.68M | $13.40M |
| Total Assets | $64.41M | $49.13M | $50.61M | $30.00M | $27.95M | $31.67M | $38.57M | $44.70M | $52.38M | $14.19M |
| Current Liabilities | $26.48M | $18.94M | $13.13M | $13.57M | $16.68M | $24.12M | $10.46M | $13.09M | $30.28M | $17.53M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $26.70M | $18.94M | $13.13M | $13.57M | $16.68M | $24.24M | $10.72M | $13.36M | $30.65M | $18.00M |
| Stockholders' Equity | $37.70M | $30.20M | $37.48M | $16.43M | $11.27M | $7.43M | $27.85M | ($14.85M) | ($24.46M) | ($3.81M) |
| Retained Earnings | ($140.65M) | ($127.83M) | ($113.16M) | ($107.15M) | ($100.70M) | ($101.27M) | ($79.75M) | ($75.65M) | ($85.50M) | ($64.54M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.24M) | - | - | - | ($8.90M) | - | - | - | ($6.46M) | - |
| Investing Cash Flow | ($5.16M) | - | - | - | ($16.0K) | - | - | - | ($6.0K) | - |
| Financing Cash Flow | $19.57M | - | - | - | $2.55M | - | - | - | $45.69M | - |
| CapEx | $8.0K | - | - | - | $16.0K | - | - | - | $6.0K | - |
| Free Cash Flow | ($6.25M) | - | - | - | ($8.92M) | - | - | - | ($6.46M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.49 | - | - | - | -15.65 | - | - | - | 0.31 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.9% | - | -11.9% | -21.5% | 2.0% | - | -10.6% | 22.0% | -40.0% | - |
| Return on equity | -34.0% | - | -16.0% | -39.2% | 5.1% | - | -14.7% | -66.4% | 85.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.40 | 2.59 | 3.83 | 2.18 | 1.64 | 1.28 | 3.61 | 3.37 | 1.71 | 0.76 |
| Quick ratio | 2.40 | 2.59 | 3.83 | 2.18 | 1.64 | 1.28 | 3.61 | 3.37 | 1.71 | 0.76 |
| Cash ratio | 1.41 | 1.54 | 3.25 | 1.65 | 1.57 | 1.08 | 3.09 | 3.19 | 1.62 | 0.55 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -489.5x | -535.6x | -399.4x | - | -416.7x | -462.6x | -460.2x | - |
| Equity multiplier | 1.71 | 1.63 | 1.35 | 1.83 | 2.48 | 4.26 | 1.39 | -3.01 | -2.14 | -3.73 |
| Liabilities / Assets | 0.41 | 0.39 | 0.26 | 0.45 | 0.60 | 0.77 | 0.28 | 0.30 | 0.59 | 1.27 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.2x | - | 2.1x | 3.6x | 63.2x | - | 13.0x | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -5.6% | - | -17.5% | 5.9% | 13.2% | - | -5.3% | -71.2% | - | - |
| Net income growth (YoY) | - | - | -46.8% | - | - | - | 5.5% | - | -43.8% | - |
| EPS growth (YoY) | -8.0% | - | 34.0% | 65.3% | 91.8% | - | -284.6% | -417.2% | -528.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 29.9% | - | - | - | -38.0% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 234.5% | 306.4% | 34.6% | - | - | - | 721.5% | 23.4% | -62.2% | -717.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Unicycive Therapeutics against the 5 most active filers in the same SIC group.